Further, these authors demonstrated in vitro that eIF4A chemical inhibition can decrease IFN-g-inducible PD-L1 expression in cell lines from a variety of human tumor types, including melanoma, breast, and colon cancer, suggesting the potential for broad applicability of this approach. The gene discussed is CD274; the disease is melanoma.